All In Biotech

Drug Trial Radar · NCT05095701

An Immunity Persistence Study of Live Attenuated Varicella Vaccine

An Open Clinical Trial to Evaluate the Immunity Persistence of Live Attenuated Varicella Vaccine At 5 and 8 Years After Primary Immunization with Live Attenuated Varicella Vaccine

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

703

Planned (sponsor's estimate)

Start

Dec 18, 2021

Primary completion

Dec 19, 2021

Study completion Oct 1, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This an open phase Ⅳ clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunity persistence of live attenuated varicella vaccine at 5 and 8 years after primary immunization with live attenuated varicella vaccine.

Conditions

  • Varicella

Interventions

  • Investigational Live Attenuated Varicella VaccineBiological

    The live attenuated varicella vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. Live attenuated varicella-virus in 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride, sodium dihydrogen phosphate, potassium dihydrogen phosphate per injection.

  • Placebo (Freeze Dired Dilution)Biological

    The placebo (freeze dired dilution) was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. and contained no active ingredient.It was 0·5 mL injection water with sucrose,sodium glutamate,sodium chloride,potassium chloride and phosphate.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity index-seropositive rates of varicella antibodyTime frame: 5 years after primary immunization
  2. Immunogenicity index-GMT of varicella antibodyTime frame: 5 years after primary immunization
  3. Immunogenicity index-the seropositive rates of varicella antibodyTime frame: 8 years after primary immunization
  4. Immunogenicity index-the GMT of varicella antibodyTime frame: 8 years after primary immunization

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Xiangcheng County Center for Disease Control and Prevention

    Xuchang, Henan, China

  • Biyang County Center for Disease Control and Prevention

    Zhumadian, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.